Ranvir’s Portfolio

Kopran Ltd –

Q3 FY 24 results and concall highlights –

Company’s business verticals –

API’s – Company has a product portfolio of 26 successfully commercialised APIs

Major APIs / segments where company is present –

Atenolol ( anti-hypertensive ) – company is one of the leaders in this molecule

Sterile Carbapenems

Sterile and Non- Sterile Cephalosporins

Macrolides

Others

Formulations – Company is only into exports of fixed dose formulations

(tablets, capsules, powders and suspensions) –

Penicillin based FDFs

Macrolides

Anti Hypertensives

Cardiovascular

Others

9M FY 24 API wise sales –

Carbapenems – 107 cr

Macrolides – 32 cr

Sterile Cephalosporins – 15 cr

Anti-Hypertensives – 32 cr

Urology antibiotics – 27 cr

Neuromodulators – 14 cr

Others – rest of API sales

Out of these, export : domestic API sales breakdown- 97 cr : 140 cr

9M FY 24 Formulation sales breakup – country wise –

South Africa – 96 cr

Africa – 53 cr

SE Asia – 20 cr

UK – 14 cr

Others – rest of formulation sales

Q3 FY 24 financial outcomes –

Revenues – 161 vs 160 cr

EBITDA – 25 vs 14 cr (huge margin expansion)

PAT – 16 vs 7 cr

Net Debt / Equity @ 0.19 pc

Margin expansion due better product mix due introduction of new products, lower RM costs, cost control initiatives. Expecting margin expansion to sustain in coming Qtrs

Company intends to get into manufacturing of KSMs to achieve better backward integration and to lower import dependence

Also intend to improve their share of sales to regulated mkts by adhering to better compliance standards

Company has invested heavily in Capex in last few years ( aprox 100 cr ). Expect Capex intensity to reduce going forward

Expect company’s new API plant at Panoli to go live in Q1 FY 25

Wrt new products, company intends to focus on anti-diabetic and cardiology products – both for regulated and unregulated markets

Company is already into contract manufacturing of APIs. This segment should expand going fwd

Once company starts making KSMs, EBITDA margins should end up touching 20 pc !!!

Company looking to clock 25-30 pc CAGR for next 2-3 yrs !!! Initially, most of this growth will be driven by semi / unregulated Mkts before the growth in regulated Mkts pick up after 2-3 yrs

Seeing very good demand outlook for Carbapenems from Domestic, Africa and LATAM mkts

Aiming to hit 1000 cr topline in 3 yrs. Additional 200-300 cr shall come from the new Panoli site. Rest from the existing facilities

These days, LATAM mkts are tightening their regulatory requirements in a meaningful way

As company improves its backward integration, aims to improve GMs beyond 40 pc for APIs and 35-40 pc for formulations

Disc: hold a small tracking position, looking to add more, biased, not SEBI registered